In clinical and experimental studies using a 3% Procapil solution, 92% of users reported a reduction in hair loss, and a noticeable improvement in the quality of thinning hair was observed. While some manufacturers add very low levels of Procapil, it is important to note that significant hair loss treatment results should not be expected from such formulations. In hereditary hair loss observed in 95% of men, it has been shown that the concentration/effectiveness ratio of 3% is ideal. The success rate seen in clinical trials has been consistently observed in standard users as well. The use of 3% Procapil solutions differs from other hair regrowth products, as most require two doses daily, while Procapil is applied as a single daily dose after the first 3 months. The success achieved with this single daily dose of 3% Procapil continues to improve.

Biotinyl-GHK, an effective peptide, ensured the retention of the hair thanks to adhesion proteins. Apigenin, with its vasodilator and flavonoid effect, inhibited the production of dihydrotestosterone (DHT) through the action of oleanolic acid derived from plant leaves, by blocking the 5a-reductase enzyme, which causes genetic hair loss.
A 4-month clinical study covering the telogen phase confirmed the noticeable anti-hair loss effect of the complex, testing its effectiveness. Morphological and immunohistochemical analyses of hair samples taken at the beginning and end of the study revealed significant changes in telogen hair bulbs, root sheaths, and the density of laminin 5 and collagen IV.